1 completed, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow KHK4083: new trials by email Literature Review of KHK4083 trials Research Report on KHK4083
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Study Assessing Rocatinlimab on Vaccine Antibody Response in Moderate-to-severe Atopic Dermatitis (AD) (ROCKET - VOYAGER) Rocatinlimab, Placebo - Atopic Dermatitis, Moderate-to-severe Atopic Dermatitis | Phase 3 | Completed | Amgen | 221 | 2023-06-07 | 2026-07-23 |
| A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD) Rocatinlimab, Placebo - Atopic Dermatitis | Phase 3 | Terminated | Amgen | 2621 | 2023-05-31 | 2026-07-16 |
Dermatitis, Atopic (2) · Eczema (1)
Amgen (2)
Canada (2) · United States (2) · Argentina (1) · Australia (1) · Austria (1) · Belgium (1) · Brazil (1) · Bulgaria (1) · Chile (1) · China (1) · Croatia (1) · Czechia (1) · Denmark (1) · Estonia (1) · Finland (1)